All the Active Ingredient Drugs
Antivirals. Sofosbuvir 400 mg, Velpatasvir 100 mg. F.C. TABS.: 28. One tab., taken oral.,
once dly. with or without food. See lit.
Treatment of chronic hepatitis C virus
(HCV) infection in adults.
C/I: Hypersens. Use with strong P gp and strong CYP induc.: Med. products that are strong P glycoprotein (P-gp) and/or strong cytoch. P450 (CYP) induc. (carbamazepine, phenobarbital, phenytoin, rifampicin, rifabutin, and St. John’s wort). Co
admin. will signific. decrease sofosbuvir
or velpatasvir plasma conc. and could
result in loss of efficacy of this formul.
Polymerase Inhibitor (Anti-HCV). Sofosbuvir 400 mg. TABS.: 28. 400 mg ×1/d with food, should be used in comb. with other medicinal products. See lit.
Indicated in comb. with other med. products for the tmt. of chronic hepatitis C (CHC) in adults. For HCV genotype specific activity.
C/I: Hypersens. Med. products that are strong P-gp inducer. (carbamazepine, phenobarbital, phenytoin, rifampicin, St. John's wort). Co-admin. will significantly decrease sofosbuvir plasma conc.
Direct-acting Antiviral. Sofosbuvir 400 mg, Velpatasvir 100 mg. F.C. TABS.: 28. 1 tab×1/d. with food. Recommen. tmt. durations for all HCV genotypes (DAA: direct-act. antivir. agent): DAA naïve pts. without cirrhosis: 8 wks. DAA naïve pts. with compensat. cirrhosis: 12 wks., 8 wks. may be consid. in genotype 3 infect. pts. DAA experience. pts. without cirrhosis/ with compensat. cirrhosis: 12 wks. See lit.
Tmt. of chronic HCV infec. in adults.
C/I: Hypersens. Concom. use with strong P-glycoprotein (P-gp) and/or strong cytochrome P450 (CYP) induc. (e.g. rifampicin, rifabutin, St. John’s wort [Hypericum perforatum], carbamazepine, phenobarbital and phenytoin).
Concom. use with rosuvastatin or dabigatran etexilate.
Concom. use with ethinylestradiol-contain. agent. e.g. comb. oral contracept. or contracept. vag. rings.